Back to Search
Start Over
Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.
- Source :
- Leukemia & Lymphoma; Apr2019, Vol. 60 Issue 4, p886-893, 8p
- Publication Year :
- 2019
-
Abstract
- We investigated whether adding radiation (RT) to systemic therapy improved outcomes in early stage diffuse large B-cell lymphoma (DLBCL) patients with or without double- or triple-hit lymphoma (DHL/THL) biology. This analysis included 183 patients profiled with fluorescent in situ hybridization (FISH) for alterations in MYC, BLC2, and/or BCL6. A total of 146 (80%) were non-DHL/THL, 27 (15%) were DHL, and 10 (6%) were THL. Systemic therapy without RT resulted in inferior freedom from relapse (FFR) (HR: 2.28; 95% CI, 1.10–4.77; p =.02). The median FFR for non-DHL/THL was not reached and was 33 and 22.3 months for DHL and THL, respectively; p <.001. Low-risk (R-IPI <2) DHL/THL patients treated with rituximab-based therapy had 3-year FFR rates of 11% and 71% for systemic therapy without and with RT, respectively; p =.04. No differences in overall survival were observed between the treatment groups. Treatment intensification with RT may improve early stage DHL/THL outcomes. [ABSTRACT FROM AUTHOR]
- Subjects :
- FLUORESCENCE in situ hybridization
LYMPHOMAS
DRAMA
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 60
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 135800901
- Full Text :
- https://doi.org/10.1080/10428194.2018.1506586